Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{185994,
        author = {U.SUPRIYA and PATHI MANI and SUNKESULA REDDY BEEBI and KOTHAPALLI UMESH},
        title = {Lenacapavir: A Novel Long-Acting Capsid Inhibitor Transforming HIV Management},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {5},
        pages = {4015-4016},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=185994},
        abstract = {Lenacapavir (GS-6207) represents a groundbreaking advancement in antiretroviral pharmacotherapy. As the first-in-class HIV-1 capsid inhibitor, it demonstrates unique multistage antiviral activity across the HIV replication cycle. Unlike conventional enzyme-targeting antiretrovirals, lenacapavir interferes with capsid assembly, nuclear import, and virion maturation. This review consolidates the molecular pharmacology, pharmacokinetics, resistance mechanisms, safety profile, and clinical efficacy of lenacapavir based on recent Phase II and III evaluations. The drug’s long half-life enabling subcutaneous dosing every six months positions it at the forefront of long-acting antiretroviral therapy and HIV pre-exposure prophylaxis, addressing adherence challenges and expanding therapeutic potential against multidrug-resistant (MDR) HIV-1 strains.},
        keywords = {Lenacapavir, HIV-1, Capsid inhibitor, Pharmacokinetics, Resistance, Long-acting therapy, PrEP.},
        month = {November},
        }